Selectivity Profiling Already At Hit Identification Stage

Drawing upon Inte:Ligand's extensive, long-term scientific experience in drug discovery and molecular de-risking, LigandScout XT offers a highly sophisticated approach to virtual screening by allowing researchers to evaluate ultra-large compound libraries against several pharmacophore models simultaneously in parallel. Instead of running isolated, single-target screens, users can employ complex Boolean logic — utilizing customized combinations of OR, AND, and NOT operators — to construct multi-dimensional screening workflows. This capability is exceptionally powerful for establishing target selectivity right from the outset; for instance, a researcher can configure a screen to identify molecules that strongly match the pharmacophore of a primary therapeutic target (AND) or a closely related beneficial isoform (OR), while explicitly filtering out any compounds that map to known anti-targets, off-target receptors, or toxicity liabilities (AND NOT).

By generating initial hit lists that are already intrinsically profiled for high selectivity, LigandScout drastically reduces late-stage attrition rates and prevents wasted resources on inherently flawed chemotypes. Furthermore, this advanced parallel screening methodology serves as an invaluable asset long after the primary discovery phase, seamlessly supporting subsequent stages like hit expansion, hit-to-lead transitions, and lead optimization. By continuously applying these Boolean combinations to evaluate evolving chemical series and new derivatives, scientists can confidently steer their molecular design processes toward highly efficacious, exquisitely selective, and rigorously de-risked clinical candidates, e.g. using the IL NeuroDeRisk Toolbox.

Contact us for an evaluation of LigandScout XT !